Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease

Journal of Vascular Access

Volumn 15, Issue 5, 2014, Pages 376-384

  Dwivedi, Amit J ^a   Roy Chaudhury, Prabir ^b   Peden, Eric K ^c   Browne, Barry J ^d   Ladenheim, Eric D ^e   Scavo, Vincent A ^f   Gustafson, Pamela N ^g   Wong, Marco D ^g   Magill, Marianne ^g   Lindow, Francesca ^g   Blair, Andrew T ^g   Jaff, Michael R ^h   Franano, F Nicholas ^g   Burke, Steven K ^g  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d California Institute of Renal Research   (United States)

^e Ladenheim Dialysis Access Centers   (United States)

^f Indiana/Ohio Heart   (United States)

^g Proteon Therapeutics Inc   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arteriovenous shunt; Graft occlusion; Pancreatic elastase; PRT 201; Renal dialysis; Vascular patency

Indexed keywords

PRT 201; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CHOLESTEROL-BINDING PROTEIN; PANCREATIC ELASTASE;

ADULT; ANGIOGRAPHY; ARTERIOVENOUS FISTULA; ARTERIOVENOUS GRAFT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLISTER; BLOOD FLOW VELOCITY; BLOOD FLOWMETRY; BLOOD VESSEL GRAFT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; ERYTHEMA; FALSE ANEURYSM; FEMALE; HEMODIALYSIS; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PAIN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; SINGLE DRUG DOSE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR PATENCY; VEIN ANASTOMOSIS; VEIN BLOOD FLOW; VEIN DIAMETER; VEIN RUPTURE; VEIN THROMBOSIS; ADVERSE EFFECTS; AGED; ARM; ARTERIOVENOUS SHUNT; BLOOD FLOW; CLINICAL TRIAL; DRUG EFFECTS; GRAFT OCCLUSION, VASCULAR; KAPLAN MEIER METHOD; MULTICENTER STUDY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SURGERY; TIME; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION; VEIN;

ADULT; AGED; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD FLOW VELOCITY; CARRIER PROTEINS; DOUBLE-BLIND METHOD; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC ELASTASE; REGIONAL BLOOD FLOW; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UPPER EXTREMITY; VASCULAR PATENCY; VEINS;

EID: 84908410099     PISSN: 11297298     EISSN: 17246032     Source Type: Journal    
DOI: 10.5301/jva.5000235     Document Type: Article

References (16)

1. NKF-KDOQI. Clinical practice guidelines for vascular Access. Am J Kidney Dis. 2006;48:S177-S247.
2. Dixon BS, Beck GJ, Vazquez MA, et al; DAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009;360(21):2191-2201.
3. Maya ID, Oser R, Saddekni S, Barker J, Allon M. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis. 2004;44(5):859-865.
4. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17(4):1112-1127.
5. Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 2009; 16(5):329-338.
6. White JJ, Ram SJ, Jones SA, Schwab SJ, Paulson WD. Influence of luminal diameters on flow surveillance of hemodialysis grafts: insights from a mathematical model. Clin J Am Soc Nephrol. 2006;1(5):972-978.
7. Burke SK, Franano FN, Mendenhall H, et al. Recombinant human elastase (PRT-201) dilates outflow veins in a rabbit mode of arteriovenous fistula. J Am Soc Nephrol. 2008;18:34A.
8. Franano FN, Hance KA, Henry C, Bland K, Burke S. PRT-201 dilates outflow veins and improves maturation rates in a rabbit model of AVF. Nephrol Dial Transplant. 2007;22:vi155-vi156.
9. Burke SK, Wong MD, Madonald K, et al. Measurement of elastin content of human cephalic vein following treatment with PRT-201, a recombinant human type I pancreatic elastase. J Am Soc Nephrol. 2012;23:967A.
10. Peden EK, Leeser DB, Dixon BS, et al. A multi-center, doseescalation study of human type I pancreatic elastase (PRT- 201) administered after arteriovenous fistula creation. J Vasc Access. 2013;14(2):143-151.
11. Amabile PG, Wong H, Uy M, et al. In vivo vascular engineering of vein grafts: directed migration of smooth muscle cells by perivascular release of elastase limits neointimal proliferation. J Vasc Interv Radiol. 2002;13(7): 709-715.
12. Wong AH, Waugh JM, Amabile PG, Yuksel E, Dake MD. In vivo vascular engineering: directed migration of smooth muscle cells to limit neointima. Tissue Eng. 2002;8(2): 189-199.
13. Beldi G, Bosshard A, Hess OM, Althaus U, Walpoth BH. Transit time flow measurement: experimental validation and comparison of three different systems. Ann Thorac Surg. 2000;70(1):212-217.
14. Chew DK, Orshal JM, Khalil RA. Elastase promotes aortic dilation by inhibiting Ca2+ influx into vascular smooth muscle. J Cardiovasc Pharmacol. 2004;43(4):504-513.
15. Qamar AA, Burke SK, Lafleur JD, et al. The ability of serum from alpha 1-antitrypsin-deficient patients to inhibit PRT- 201, a recombinant human type I pancreatic elastase. Biotechnol Appl Biochem. 2012;59(1):22-28.
16. Hye RJ, Peden EK, O'Connor TP, et al. Human type I pancreatic elastase treatment of arteriovenous fistulae in patients with chronic kidney disease. J Vasc Surg. 2014; in press.